Method for treating or preventing thrombosis using dabigatran etexilate or a salt thereof with improved safety profile over conventional warfarin therapy

Details for Australian Patent Application No. 2009315729 (hide)

Owner Boehringer Ingelheim International GmbH

Inventors Reilly, Paul A.

Agent Spruson & Ferguson

Pub. Number AU-A-2009315729

PCT Pub. Number WO2010/055021

Priority 61/113,404 11.11.08 US; 61/237,552 27.08.09 US

Filing date 10 November 2009

Wipo publication date 20 May 2010

International Classifications

A61K 31/4439 (2006.01)

A61P 7/02 (2006.01) Drugs for disorders of the blood or the extracellular fluid

Event Publications

12 May 2011 PCT application entered the National Phase

  PCT publication WO2010/055021 Priority application(s): WO2010/055021

Legal

The information provided by the Site not in the nature of legal or other professional advice. The information provided by the Site is derived from third parties and may contain errors. You must make your own enquiries and seek independent advice from the relevant industry professionals before acting or relying on any information contained herein. Check the above data against the Australian Patent Office AUSPAT database.

Next and Previous Patents/Applications

2009315730-Method for treating or preventing thrombosis using dabigatran etexilate or a salt thereof with improved efficacy over conventional warfarin therapy

2009315726-Carbon black granulate, method for producing carbon black granulate, and use thereof